KMD Bioscience has dedicated years of research to the field of antibodies. The acquisition of the gene sequence of monoclonal antibodies from hybridoma cells is the foundation for recombinant antibody production and antibody drug development. We have an experienced sequencing technology team with excellent primer design and antibody gene analysis capabilities, able to provide accurate and rapid Monoclonal Antibody Sequencing Services to ensure the precise reconstruction of the target antibody before entering downstream applications.

We promise to provide fast, complete, and highly reliable sequencing results. We are capable of accurately and proficiently sequencing hybridoma cells derived from multiple species, including mouse hybridoma cells, rat hybridoma cells, rabbit hybridoma cells, and recombinant monoclonal antibodies from various species (antibody genes obtained through phage technology). We ensure high accuracy through stringent quality control.

In the process of producing recombinant antibodies, customers may encounter issues after PCR, such as the occurrence of two heavy chains and two light chains, leading to diversity in the heavy and light chain pairing, making recombinant antibody production time-consuming and labor-intensive. We solve this problem by designing a series of IgG primers for myeloma cells and combining them with subcloning technology, enabling the acquisition of sequence information that closely matches the target antibody.

Additionally, we can engineer and purify your valuable antibodies using our advanced codon optimization and gene synthesis strategies. We also have a comprehensive High-Throughput Recombinant Antibody Expression Platform and Bioinformatics Platform. After sequencing, we provide Recombinant Antibody Expression Validation. Through database comparison and analysis of the variable region structure, we ensure the accuracy of the delivered sequence. We also offer De novo Sequencing Services, N-terminal Sequencing, and Protein Theoretical Coverage Detection Services for Recombinant Antibodies. With a complete Antibody Platform, we provide a one-stop technical service, from antigen production, antibody development, hybridoma cell antibody gene sequencing, to chimeric antibody production, recombinant antibody expression, and humanized antibody development, catering to a variety of customer needs.